

Menopur® (menotropins for injection) – Status Update

09 January 2022 – Ferring Pharmaceuticals is committed to providing safe and effective treatments for patients.

Where applicable and in accordance with feedback received from health authorities, Ferring has resumed shipments of Menopur® in the United States and other countries.

Ferring suspended shipments after the company was made aware of changes in the manufacturing process of the drug substance for Menopur.

Ferring notified national health authorities and - as a precautionary measure - suspended all shipments of Menopur* (all presentations).

Data reviewed by Ferring to date indicates that the safety and efficacy of the product remains unaltered. Ferring is not aware of any evidence indicating that the changes in the manufacturing process pose any risks to patients.

Ferring understands the importance of Menopur to our patients, physicians, and customers and sincerely regrets any inconvenience caused by this supply disruption. The company is working with national health authorities in each country where the product is marketed and will provide updates when available.

In the meantime, for global medical enquiries contact Ferring at GlobalMedical@ferring.com. For U.S. medical enquiries call 1-888-FERRING (1-888-337-7464), or email MedQueriesUS@ferring.com.

*Menopur, Merapur, Menogon HP, Menotrophin Ferring, HMG injection, Menotropin